



4000 P236H
0/516340
Rec'd PCTO 30 NOV 2004

The Patent Office
INVESTOR IN PEOPLE
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 23 JUN 2003

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed *Andrew Gersey*
Dated 23 June 2003

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

THE PATENT OFFICE

A

31 MAY 2002



02JUN02 E723018-1 010100
P01/7700 0.00-0212667.0

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

P/193/GBA

2. Pa
(n)

0212667.0

31 MAY 2002

3. Full name, address and postcode of the or of each applicant (*underline all surnames*)

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

pSiMedica Limited
Malvern Hills Science Park
Geraldine Road
Malvern
Worcestershire
WR14 3SZ
GB

Texas Christian University
TCU Box 298860
Forth Worth
TX 7612
US

839 506 3001

ae
11/7
1.7.0

4. Title of the invention

Orthopaedic Scaffolds for Tissue Engineering

5. Name of your agent (*if you have one*)

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

Patents ADP number (*if you know it*)

Carol P. Greaves et al.

Greaves Brewster
24A Woodborough Road
Winscombe
North Somerset
BS25 1AD
GB

Indigo House
Cheddar Business Park
Wedmore Road
Cheddar
Somerset
BS27 3EB

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number
(*if you know it*)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Yes

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

14 ✓

Claim(s)

4 ✓

Abstract

1 ✓

Drawing(s)

2 + 2

CF

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

One

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date 30/5/02

12. Name and daytime telephone number of person to contact in the United Kingdom

Carol Greaves 01934 844419

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.

DUPLICATE

1

Orthopaedic Scaffolds for Tissue Engineering

The present invention relates to processes for making self-assembly orthopaedic scaffolds for tissue engineering, and to the
5 orthopaedic scaffolds obtained thereby.

Background of the Invention

Tissue engineering (TE) embodies a major new trend in medicine that
10 is helping the body to heal itself. Engineering new bone is expected to be an important TE area over the next decade since bone & cartilage are simpler cellular systems and the body already has an in-built regeneration system ("remodelling") for bone.

15 The need for bone replacement can arise from trauma, infection, cancer or musculoskeletal disease. Every year, surgeons in the USA alone perform over 450,000 bone grafts. Both natural and synthetic materials are used in a variety of approaches.

20 A bone autograft is a portion of bone taken from another area of the skeletal system of the patient. Autografting is considered the gold standard in efficacy for procedures that require supplemental bone, but autograft harvest carries risks and considerable patient discomfort. Recovery time is slow and often exceeds 6 months.

25 Alternatives are bone allografts, involving a human donor source other than the recipient patient. An allogenic bone graft, commonly derived from human cadavers, is cleaned, sterilised, and stored in a bone bank prior to use. However the sterilization
30 process may be compromise the strength of the bone, and there is a perceived risk of transmitting infectious disease. It is also known to have limited osteoconductive and osteoinductive

capabilities, the importance of which is discussed more fully below.

5 A bone xenograft, in which processed bone from animals is transplanted to humans offers higher productivity but is perceived to be riskier than allografting in terms of disease transmission.

10 A range of bone graft materials have been in clinical use for some time and others are under development. Approved natural products include demineralised human bone matrix, bovine collagen mineral composites and processed coralline hydroxyapatite. Synthetic products which are approved include calcium sulphate scaffolds, bioactive glass scaffolds and calcium phosphate scaffolds. These materials are required to have a number of particular physical and 15 biological properties.

Orthopaedic scaffolds are used as both temporary or permanent conduits for bone. They can both encourage and direct growth across a fracture site, or regrowth of damaged or infected bone. Whilst 20 the composition of cortical and cancellous bone is very similar, their microstructure differs considerably. Compact or cortical bone contains neurovascular "Haversian" canals of about 50-100 micron width, which are held together by a hard tissue "stroma" or "interstitium". The structure of spongy, cancellous bone differs 25 from cortical bone in being more open-spaced and trabecular.

Any material used in an orthopaedic scaffold is required to have a porosity which closely reflects that of the bone it is intended to replace. For example, a biomimetic scaffold for cancellous bone 30 would have a thin interstitium lattice interconnected by pores of 500-600 micron width. It is the interstitium which does not have blood within, that can be substituted by a biodegradable composite material.

In addition, in order for an implant to be used as a replacement for bone it must be capable of at least allowing osteointegration and osteoconduction. Osteointegration refers to the direct chemical bonding of a biomaterial to the surface of bone without a
5 thick intervening layer of fibrous tissue.

An osteoconductive biomaterial passively allows living bone to grow and remodel over its surface. Normal osteoblast behaviour is thus maintained which includes mineralisation, collagen production and
10 protein synthesis.

Two desired further properties for an OTE scaffold material are that it is osteoinductive or osteogenic, and degradable at a rate that matches that of new bone in-growth.
15

An osteoinductive biomaterial actively encourages bone growth, by for example, recruiting and promoting the differentiation of mesenchymal stem cells into osteoblasts. An osteoinductive implant will often induce bone to grow in areas where it would not normally
20 grow i.e. "ectopic" bone formation. This induction process is normally biochemical, but it could be mechanical or physical in nature. Finally, an osteogenic biomaterial is one that contains cells that can form bone or can differentiate into osteoblasts.

25 Typical requirements on biodegradation rates are that the scaffold maintains its structural integrity for 4-10 weeks for cartilage repair and 3-8 weeks for bone repair

The mechanical requirements of the material are highly dependant on
30 the type of tissue being replaced. Cortical bone has a Youngs Modulus of 15-30 GPa, cancellous (spongy, trabecular) bone has a Youngs Modulus of 0.01-2GPa and cartilage has a Youngs Modulus of

less than 0.001 GPa and the material used in any particular case should reflect this as far as possible.

Many approaches to fabricating porous scaffolds have been developed for biodegradable polymer systems, these include solvent casting and particulate leaching, melt moulding, fibre bonding, gas foaming or membrane lamination.

Different approaches are known for the more thermally stable ceramic systems such as hydrothermal conversion and burn-out of dispersed polymer phase.

Many of the existing porous biodegradable polymeric systems have been found to have limitations for use as orthopaedic scaffolds for cell ingrowth. For instance, it is often possible only to obtain a poor match of mechanical properties to the tissue being replaced. There is difficulty in achieving uniform porosity over large distances within the polymeric system, and although matrices can be osteoconductive, they may not have any osteoinductive ability.

Porous ceramic systems also suffer from poor control over pore size distribution, and may also have poor moldability compared to polymers.

To address some of these deficiencies, more complex scaffolds are under development, such as polymer/ceramic composites, seed polymer scaffolds with mesenchymal stem cells and biomaterial/tissue hybrid structures.

WO 98/44964 discloses biocompatible compositions comprising porous biodegradable polymer having bioactive material such as silicon compounds (silica-gel or bioactive glass) for the replacement of bone grafts.

WO 01/95952 A1 describes the use of bioactive and biodegradable silicon in orthopaedic scaffolds. In particular, silicon is shaped to the desired shape and then porosified electrochemically, to form bioactive material. A significant limitation of nanostructuring silicon via electrochemistry is the inability to anodise across the depths needed for large implants. In another embodiment, porous silicon powder is mixed with powder of a biodegradable polymer (polycaprolactone), which is melted together to form a bioactive composite for orthopaedic use. There is however no disclosure as to how large channels for bone in-growth could be realized in such composites.

The applicants have found that orthopaedic scaffolding can advantageously be prepared from materials of this type using a particular self assembly method.

Summary of the Invention

According to the present invention there is provided a method of preparing an orthopaedic scaffold, said method comprising forming shaped blocks of a bioactive material comprising silicon, treating one or more selected surfaces of said blocks such that they will adhere to a similarly treated surface of a similar block, and combining two or more of said blocks together under conditions in which the treated surfaces will bind together.

As used herein, the term "blocks" refer to polygon shaped, three-dimensional structures. They may have a variety of shapes to suit the desired construction, including polygons or spheroidal shapes with one or more planar regions. Typically they will be square, hexagonal or octagonal in cross section. Suitably, they are hollow or have a central hole. They will generally be relatively small in size, for example from 1-8mm and preferably from 1.5-5mm across. In particular, they will comprise cubes which are, for example 3mm

x 3mm x 3mm, or cuboids of similar dimensions in cross section but with a reduced depth for example of from 0.8 to 0.9 mm, hexagons which for example, range from 1.9 to 3.9 mm across, which a depth of 0.8 to 0.84mm

5

Suitably the blocks will be at least partially porous, and preferably with a porosity in the range of from 10 to 90%, and preferably in the range of from 30 to 80%, most preferably from 35%-58%. Porosity values of from 30 to 80% can be produced for
10 example, by introduction of 2mm channels in 1,2 or 3 dimensions into the block. Higher porosity values may be possible by including soluble salts into the materials used to prepare the blocks (for example a mixture of bioactive silicon powder and polymer described hereinafter), and the subsequent removal of the
15 salt by incubation in aqueous media. This will allow it to be used in the context of the various types of bone structures described above.

20

Using the method of the invention, it is possible to obtain the larger scaffolds needed for most bone grafts with the desired nanostructure throughout. Furthermore, the scaffolds will have highly ordered structures. For bone grafts this translates into excellent control of macroporosity and macropore architecture

25

Suitably, the bioactive material used comprises bulk crystalline silicon, porous silicon, amorphous silicon or polycrystalline silicon, as well as composites of bioactive silicon and other materials, as described in WO 01/95952. In particular however, the bioactive material used in the method of the invention comprises a
30 composite of bioactive silicon and a biocompatible polymer.

Silicon is suitably present in the composite in the form of polycrystalline or porous particles, which are fused to polymer

carrier material. These are suitably formed by pre-forming the desired bioactive silicon particles, mixing these with the polymer carrier material, also in powder or granular form, and heating the resultant mixture so as to fused the mixture. Suitably the polymer
5 is a low melting polymer, for example with a melting point of less than 150°C and preferably less than 100°C so that the melting process can be carried out without losing the nanostructure of the silicon particles.

10 Particular examples of suitable polymers include polycaprolactone (PCL), poly(3-hydroxybutyrate (PHB), poly(lactic acid) (PLA), polyglycolic acid (PGA), polyanhydrides, polyorthoesters, polyiminocarbonates, polyphosphazenes and polyamino acids. Preferably the polymer used in the composite is PCL with a
15 molecular weight in the range of from about 2kD up to 15 kD product.

Silicon used in the method of the invention may be bioactive silicon, resorbable silicon or biocompatible silicon. As used
20 herein, the term "bioactive" refers to components that bind to tissue. Resorbable silicon is defined as being silicon which dissolves over a period of time when immersed in simulated body fluid solution. "Biocompatible" refers to materials which are acceptable for at least some biological applications, and in
25 particular may be compatible with tissue.

These properties depend upon the physical form of the silicon, in particular whether it is porous, polycrystalline, amorphous or bulk crystalline and are described in more detail in WO 97/06101.
30

Depending upon the particular use and mode of action of the desired orthopaedic scaffold, inclusion of porous and/or polycrystalline silicon may be preferred because these nanostructured forms have

been found to promote calcification and hence bone bonding. The semiconductor properties of the porous and/or polycrystalline silicon opens the way for electrical control of the treatment, repair or replacement process. Furthermore porous silicon and particularly mesoporous silicon having a pore diameter in the range of from 20 to 500Å, and polycrystalline silicon of nanometer size grains has been found to be resorbable. Corrosion of silicon during the resorption process produces silicic acid, which is known to stimulate bone growth.

10

Silicon having these properties may be obtained, for example by electrolysis of silicon wafers, as described for example in WO 97/06101, as silicon nanocrystals from pyrolysis reactions, from silicon nanowires and/or as microcrystalline silicon.

15

The mass ratio of silicon:organic polymer in the composite is suitably in the range of from 1:99 to 99:1 and preferably from 1:20 to 1:4w/w.

20

Nanostructured silicon/polymer composites are particularly preferred for use in the method of the invention since they provide good moldability combined with bioactivity. In addition, they have tunable mechanical properties for a fixed chemistry which is helpful for the regulatory process. The porosity of the blocks may be readily "tailored" to the desired porosity through physical deformation. It will in any event, be largely dependent upon the amount of composite placed in a given mold during structure fabrication, and may if desired or necessary be modified following production for example by a wet chemical etching process, or a salt incorporation followed by selective leaching.

25
30

Treatment of the selected surfaces may be carried out in various ways, provided it leads to the "activation" of the surface to

binding. In particular, it produces reactive groups on the surface, which are able to react, for example with coupling agents, to form covalent bonds, which hold the blocks firmly together. Examples of such reactive groups include silanol groups (SiOH).

5

Treatments may be effected chemically, for example using the techniques described in WO 00/26019 or WO 00/66190. However, it is difficult to limit chemical derivatization to particular surface areas, and therefore a preferred method comprises activating the surface by exposing the surface to an activating radiation or plasma. In particular, the applicants have found that a brief exposure, for example of from 15 seconds to 1 hour or more preferably from 1-10 minutes, of the selected surfaces to oxygen-rich plasma will increase the density of silanol (Si-OH) moieties on the surfaces as well as etching away some of the surface polymer (where present), and so further expose the crystalline Si domains.

15

Suitable coupling reagents will depend upon the form of the activation of the surface. However, when using oxygen plasma as outlined above, suitable coupling agents include alkoxysilane reagents such as tetraethoxysilane (TEOS), tetramethoxysilane (TMOS), aminopropyltriethoxysilane (APTES) or mercaptopropyltrimethoxysilane (MPTS).

20

The coupling reagent is suitably dissolved in a solvent such as water, at concentrations of from 0.0015 to 0.0132 molar. The higher the concentration of coupling agent, the greater the degree of coupling which will occur, and thus, this will affect the dimensions of the final structure which may be achieved. Pre-treated blocks are then mixed in the solution of the coupling reagent with stirring, until the desired structure has been formed. Suitably, the reaction duration and coupling reagent concentration

30

is set so that the structure will be obtained within a period of from 5 to 30 minutes.

- 5 The selection of the surfaces which are treated in this way depends upon the construction being produced. In order to produce essentially "one dimensional" shapes, the upper and/or lower surface of the blocks is treated. This means that when they combine together, they pile up in an essentially columnar arrangement.
- 10 For the creation of essentially two dimensional structures, side edges of the blocks are suitably treated. In this way, the blocks will pack together alongside one another. For truly three dimensional structures, at least some of each of the side and/or upper and lower surfaces will be pre-treated before the mixing
- 15 process begins.

- If desired, once the scaffold has been prepared as described above, other surface modification reactions may be carried out to alter the biological specificity. For example, APTES may be coupled to
- 20 the surface, together with other small peptides, which alter vascular growth endothelial factor (VGEF) activity or other cellular recognition/adhesion in vivo.

- The stability of the assembled structure may also be improved by
- 25 application of heat.

The invention further comprises an orthopaedic scaffold, obtainable by a process as described above.

- 30 Thus the invention further provides an orthopaedic scaffold comprising a plurality of blocks of a bioactive material comprising silicon, adhered together. In particular the bioactive material comprises a composite of silicon and a biocompatible polymer as

described above. Suitably, also, the blocks are adhered together by means of covalent bonds.

Orthopaedic scaffolds in accordance with the invention may have a
5 variety of applications. For example, they may be used in the treatment of hip fracture, arthrosis of the hip and knee, vertebral fracture, spinal fusion, long bone fracture, soft tissue repair and osteoporosis.

10 The process of the invention may have wider applications, for example in the preparation of other bodies comprising silicon, and in particular medical devices or implants which are required to be bioactive. Furthermore, the formation of covalent chemical bonds
15 between elements of a "self-assembled" polymer body has not previously been carried out. Earlier self-assembly strategies of micro/millimeter scale polymer objects have employed non-biocompatible or non-bioactive polymers (such as Poly
DiMethylSiloxane (PDMS)) whose condensed long range order is made manifest by physical capillary forces. Using the method of the
20 invention, it is possible to produce covalent chemical bonds, and particularly strong covalent interfacial bonds between blocks. This strategy may find application in the production of solid bodies for a variety of non-medical purposes as well as those listed above.

25 Thus in a further aspect, the invention provides a process for preparing solid object, said process comprising forming shaped blocks of a material comprising silicon, treating one or more selected surfaces of said blocks such that they will adhere to a
30 similarly treated surface of a similar block, and combining two or more of said blocks together under conditions in which the treated surfaces will bind together, and thereafter recovering the assembled structure.

Suitably in this process, covalent chemical bonds are formed between the surfaces to bind the blocks together. Preferred options for carrying out are similar to those described above.

- 5 Still further, the invention provides a process for preparing a solid object, said process comprising forming shaped blocks of a material, treating one or more selected surfaces of said blocks such that they will adhere to a similarly treated surface of a similar block, and combining two or more of said blocks together
10 under conditions in which the treated surfaces will form covalent chemical bonds therebetween, and thereafter recovering the assembled structure.

- Again, preferred means of carrying out this process will be
15 analogous to those described above.

Description of the Figures

- Figure 1 shows typical monomer blocks of a polycaprolactone/silicon composite, which are either hexagonal (a) and of 3mm diameter, or
20 cuboid with a 4mm edge length.

- Figure 2 shows one dimensional assemblies formed from the hexagonal blocks of Figure 1, wherein (a) comprises a tetramer of hexagons, and (b) comprises a pentamer of hexagons.

- 25 Figure 3 shows two dimensional networks comprising (a) a trimer of hollow hexagonal blocks, (b) a close packed array of solid hexagonal blocks and (c) a tile of 8 cubes.

- 30 Figure 4 shows a three dimensional scaffold, comprising an octamer of cubes.

Detailed Description of the Invention

Example 1

Step 1

Synthesis of individual structures:

- 5 The individual composite building blocks (in the form of cubes or hexagons) were prepared by initially grinding polycaprolactone (PL) with the porous powdered silicon material, obtained as described in WO01/95952, in various ratios by mass. The ratios prepared were as follows:

10

Product	Mass of PL Powder	Mass of porous silicon powder
1-D pentamer (Fig. 2b)	0.3077g	0.0596g
2-D trimer (Fig. 3a)	0.4181g	0.0827g
2-D hexamer (Fig. 3b)	0.1652g	0.0338g
2-D octamer (Fig. 3c)	0.6614g	0.1335g
3-D octamer (Fig. 4)	0.6403g	0.1315g

- These composite powders were then poured into pre-formed PDMS molds with the desired 2-D shape (hexagonal or square). The molds were heated in an oven at 110°C for ~ 1 hr, and then cooled to room temperature. The solid composite blocks obtained could then be cut to the desired thickness between 0.8mm to 4mm.

15

Step 2

Preparation of Organized Assemblies:

- 20 The 2-D octamer illustrated in Figure 3c was prepared as follows. Predetermined surfaces of the blocks obtained in Step 1 were exposed to a brief (8 minutes long) oxygen-rich plasma in order to etch away some of the surface PCL, expose the crystalline Si domains, and increase the density of silanol (Si-OH) moieties on the surface. Eight blocks were added to a 0.0063 molar aqueous solution of MPTS together with 2.8ml of ethanol at room

25

temperature, and stirred for 30 minutes until the desired structure was achieved.

Other assemblies were prepared in an analogous manner. Examples of 1D, 2D and 3D assemblies prepared in this way are shown in figures 2-4.

Example 2

Biological Testing

10 Scaffolds obtained using the method of the invention may be tested to determine their precise properties. In particular, the calcification activity, the silicon dissolution kinetics and the phase behavior at the polymer/Si interface (blending or separation - direct visualization of morphology) as well as the mechanical strength can be tested using conventional methods.

20 By varying the process parameters, such as the nature of the bioactive material and particularly the composite material, the size and shape of the blocks, the concentration of the coupling reagent and the length of time the blocks are immersed in it, a wide variety of orthopaedic scaffolds suitable for different purposes may be obtained.

Claims

1. A process for preparing an orthopaedic scaffold, said process comprising forming shaped blocks of a bioactive material comprising silicon, treating one or more selected surfaces of said blocks such that they will adhere to a similarly treated surface of a similar block, and combining two or more of said blocks together under conditions in which the treated surfaces will bind together, and thereafter recovering the assembled structure.
2. A process according to claim 1 wherein the said blocks are square or hexagonal in cross section.
3. A process according to claim 1 or claim 2 wherein the blocks will be at least partially porous.
4. A process according to any one of the preceding claims wherein the bioactive material comprises bulk crystalline silicon, amorphous silicon, porous silicon, polycrystalline silicon, or a composite of bioactive silicon and another material.
5. A process according to claim 4 wherein the bioactive material is a composite of bioactive silicon and a biocompatible polymer.
6. A process according to claim 5 wherein the composite is obtained by mixing bioactive silicon particles with a polymer in powder or granular form, and heating the resultant mixture so as to fuse it.
7. A process according to claim 6 wherein the mixture is heated in a mold to form a block of a desired shape.

8. A process according to claim 6 wherein the polymer has a melting point of less than 150°C.

9. A process according to any one of claims 5 to 8 wherein the biocompatible polymer is polycaprolactone.

10. A process according to any one of claims 5 to 9 wherein the mass ratio of silicon:organic polymer in the composite is from 1:99 to 99:1.

11. A process according to claim 10 wherein the mass ratio of silicon: organic polymer is in the range of from 1:20 to 1:4w/w.

12. A process according to any one of the preceding claims wherein the surfaces bind together by forming covalent chemical bonds therebetween.

13. A process according to any one of the preceding claims wherein the said one or more surfaces of the blocks are treated so as to increase the density of silanol groups (SiOH) thereon.

14. A process according to claim 13 wherein the said one or more surfaces are exposed to an oxygen-rich plasma, and thereafter mixed with similarly treated blocks in the presence of a coupling agent.

15. A process according to claim 14 wherein the coupling agent is an alkoxysilane.

16. A process according to claim 15 wherein the alkoxysilane is in aqueous solution.

17. A process, according to any one of the preceding claims wherein the surface of the assembled structure is treated to alter its biological specificity.
- 5 18. A process according to any one of the preceding claims wherein the assembled structure is heated to raise its mechanical strength.
- 10 19. An orthopaedic scaffold, obtainable by a process according to any one of claims 1 to 18.
20. An orthopaedic scaffold comprising a plurality of blocks of a bioactive material comprising silicon, adhered together.
- 15 21. An orthopaedic scaffold according to claim 20 wherein the bioactive material comprises a composite of silicon and a biocompatible polymer.
- 20 22. An orthopaedic scaffold according to claim 20 or claim 21 wherein the blocks are adhered together by means of covalent bonds.
- 25 23. A process for preparing solid object, said process comprising forming shaped blocks of a material comprising silicon, treating one or more selected surfaces of said blocks such that they will adhere to a similarly treated surface of a similar block, and combining two or more of said blocks together under conditions in which the treated surfaces will bind together, and thereafter recovering the assembled structure.
- 30 24. A process according to claim 23, wherein covalent chemical bonds are formed between the surfaces to bind the blocks together.

25. A process for preparing solid object, said process comprising forming shaped blocks of a material, treating one or more selected surfaces of said blocks such that they will adhere to a similarly treated surface of a similar block, and combining two or more of
5 said blocks together under conditions in which the treated surfaces will form covalent chemical bonds therebetween, and thereafter recovering the assembled structure.

26. A process for preparing an orthopaedic scaffold substantially
10 as hereinbefore described with reference to the Examples.


Abstract

Orthopaedic Scaffolds for Tissue Engineering


- 5 A process for preparing an orthopaedic scaffold, or other solid body, said process comprising forming shaped blocks of a bioactive material comprising silicon, treating one or more selected surfaces of said blocks such that they will adhere to a similarly treated surface of a similar block, and combining two or more of said
- 10 blocks together under conditions in which the treated surfaces will bind together, and thereafter recovering the assembled structure.

Products including orthopaedic scaffolds obtained using this process are also enclosed.

Figure 1




(a)




(b)

Figure 2



(a)




(b)


Figure 3



(a)




(b)



(c)

Figure 4



THE PATENT OFFICE
23 JUN 2003
Received in Patents
International Unit